Table 1 Perioperative and intraoperative parameters of the two study cohorts after the stage one lung wedge resection. Continuous variables were expressed in mean \(\pm\) standard deviation. For each clinical characteristics shown in the above table, no significant difference was found among the control group and treatment group at a 5% significance level. It showed covariate balance between control and treatment groups.
From: Non-steroidal anti-inflammatory drugs reduce pleural adhesion in human: evidence from redo surgery
Clinical characteristic | Treatment, with NSAIDa (n = 27) | Control, without NSAID (n = 17) | p-Value (2-sided test) |
|---|---|---|---|
Age | 61.7 ± 6.8 | 62.1 ± 7.5 | 0.88 |
Smoker | 6 (22.2%) | 7 (41.2%) | 0.32 |
Diabetic | 5 (18.5%) | 5 (29.4%) | 0.64 |
Hypertension | 8 (29.6%) | 7 (41.2%) | 0.65 |
Asthma | 0 (0%) | 1 (5.9%) | 0.39 |
History of Malignancy | 9 (33.3%) | 10 (58.8%) | 0.18 |
History of Oncological therapy | 5 (18.5%) | 5 (29.4%) | 0.40 |
Forced expiratory volume in one second (% predicted) | 96.9 ± 14.9 | 87 ± 19.9 | 0.07 |
Diffusing capacity for carbon monoxide (% predicted) | 99.2 ± 15.9 | 89.7 ± 20 | 0.09 |
Upper lobe resection | 14 (51.9%) | 8 (47.1%) | 1.00 |
Uniportal VATSb | 21 (77.8%) | 14 (82.4%) | 1.00 |
Right-side operation | 21 (77.8%) | 10 (58.8%) | 0.32 |
Visceral pleural sealants | 7 (25.9%) | 3 (17.6%) | 0.72 |
Smaller chest drain size (Fr 24) | 21 (77.8%) | 14 (82.4%) | 1.00 |
Chest drain duration (days) | 4.1 ± 2.5 | 4.6 ± 4.1 | 0.63 |
Length of stay (days) | 5.8 ± 2.9 | 6.4 ± 3.2 | 0.55 |
Waiting time for redo operation (days) | 104.8 ± 85.8 | 106 ± 73.9 | 0.96 |
